

Publikationsliste 2013

1. Abdelhady W, Bayer AS, Seidl K, Nast CC, Kiedrowski MR, Horswill AR, Yeaman MR, Xiong YQ. Reduced vancomycin susceptibility in an in vitro catheter-related biofilm model correlates with poor therapeutic outcomes in experimental endocarditis due to methicillin-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother*. 2013; 57(3): 1447-54.
2. Abdel-Mohsen M, Deng X, Liegler T, Guatelli JC, Salama MS, Ghanem Hel D, Rauch A, Ledergerber B, Deeks SG, Gunthard HF, Wong JK, Pillai SK. Effects of Alpha Interferon Treatment on Intrinsic Anti-HIV-1 Immunity In Vivo. *Journal of virology*. 2013. [Epub ahead of print]
3. Achermann Y, Eigenmann K, Ledergerber B, Derksen L, Rafeiner P, Clauss M, Nuesch R, Zellweger C, Vogt M, Zimmerli W. Factors associated with rifampin resistance in staphylococcal periprosthetic joint infections (PJI): a matched case-control study. *Infection*. 2013; 41(2): 431-7.
4. Achermann Y, Rossle M, Hoffmann M, Deggim V, Kuster S, Zimmermann DR, Bloemberg G, Hombach M, Hasse B. Prosthetic valve endocarditis and bloodstream infection due to *Mycobacterium chimaera*. *J Clin Microbiol*. 2013;51(6): 1769-73.
5. Achermann Y, Sahin F, Schwyzer HK, Kolling C, Wust J, Vogt M. Characteristics and outcome of 16 periprosthetic shoulder joint infections. *Infection*. 2013; 41(3): 613-20.
6. Aebi-Popp K, Mulcahy F, Glass TR, Rudin C, Martinez de Tejada B, Bertisch B, Fehr J, Grawe C, Scheibner K, Rickenbach M, Hoesli I, Thorne C. Missed opportunities among HIV-positive women to control viral replication during pregnancy and to have a vaginal delivery. *J Acquir Immune Defic Syndr*. 2013;64(1): 58-65.
7. Anagnostopoulos A, Rotger M, Aouri M, Kuster SP, Telenti A, Decosterd LA, Gunthard HF. Efavirenz intoxication due to a new CYP2B6 constellation. *Antivir Ther*. 2013;18(5):735-738.
8. Bartha I, Carlson JM, Brumme CJ, McLaren PJ, Brumme ZL, John M, Haas DW, Martinez-Picado J, Dalmau J, Lopez-Galindez C, Casado C, Rauch A, Gunthard HF, Bernasconi E, Vernazza P, Klimkait T, Yerly S, O'Brien SJ, Listgarten J, Pfeifer N, Lippert C, Fusi N, Kutalik Z, Allen TM, Muller V, Harrigan PR, Heckerman D, Telenti A, Fellay J. A genome-to-genome analysis of associations between human genetic variation, HIV-1 sequence diversity, and viral control. *eLife*. 2013; 2: e01123.
9. Beerenwinkel N, Montazeri H, Schuhmacher H, Knupfer P, von Wyl V, Furrer H, Battegay M, Hirschel B, Cavassini M, Vernazza P, Bernasconi E, Yerly S, Boni J, Klimkait T, Cellera C, Gunthard HF, Swiss HIVCS. The individualized genetic barrier predicts treatment response in a large cohort of HIV-1 infected patients. *PLoS Comput Biol*. 2013; 9(8): e1003203.

10. Bernasconi M, Ueda S, Krukowski P, Bornhauser BC, Ladell K, Doner M, Sigrist JA, Campidelli C, Aslandogmus R, Alessi D, Berger C, Pileri SA, Speck RF, Nadal D. Early gene expression changes by Epstein-Barr virus infection of B-cells indicate CDKs and survivin as therapeutic targets for post-transplant lymphoproliferative diseases. *International Journal of Cancer* 2013; 133(10):2341-2350.
11. Bertisch B, Franceschi S, Lise M, Vernazza P, Keiser O, Schoni-Affolter F, Bouchardy C, Dehler S, Levi F, Jundt G, Ess S, Pawlita M, Kovari H, Wandeler G, Calmy A, Cavassini M, Stockle M, Clifford G. Risk factors for anal cancer in persons infected with HIV: a nested case-control study in the Swiss HIV Cohort Study. *Am J Epidemiol.* 2013; 178(6): 877-84.
12. Boillat-Blanco N, Darling KE, Taffe P, Osih R, Strahm C, Adami M, Elzi L, Daou S, Fehr J, Wandeler G, Cavassini M. Impact of recommendation updates in well-controlled patients on nonrecommended antiretroviral therapies: the Swiss HIV cohort study. *J Acquir Immune Defic Syndr.* 2013; 62(2): 180-9.
13. Bostanci N, Thurnheer T, Aduse-Opoku J, Curtis MA, Zinkernagel AS, Belibasakis GN. Porphyromonas gingivalis Regulates TREM-1 in Human Polymorphonuclear Neutrophils via Its Gingipains. *PLoS One.* 2013; 8(10):e75784.
14. Braun J, Held L, Ledergerber B, and Swiss HIV Cohort Study. Accounting for baseline differences and measurement error in the analysis of change over time. *Stat Med.* 2013 [Epub ahead of print]
15. Brennan DC, Aguado JM, Potena L, Jardine AG, Legendre C, Saemann MD, Mueller NJ, Merville P, Emery V, Nashan B. Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms. *Rev Med Virol.* 2013; 23(2): 97-125.
16. Bucheli E, Kralidis G, Boggian K, Cusini A, Garzoni C, Manuel O, Meylan PR, Mueller NJ, Khanna N, van Delden C, Berger C, Koller MT, Weisser M, the Swiss Transplant Cohort S. Impact of enterococcal colonization and infection in solid organ transplantation recipients from the Swiss Transplant Cohort Study. *Transpl Infect Dis.* 2013. [Epub ahead of print]
17. Conen A, Wang Q, Glass TR, Fux CA, Thurnheer MC, Orasch C, Calmy A, Bernasconi E, Vernazza P, Weber R, Bucher HC, Battegay M, Fehr J. Association of alcohol consumption and HIV surrogate markers in participants of the swiss HIV cohort study. *J Acquir Immune Defic Syndr.* 2013; 64(5): 472-8.
18. Cosgrove C, Ussher JE, Rauch A, Gartner K, Kurioka A, Huhn MH, Adelman K, Kang YH, Fergusson JR, Simmonds P, Goulder P, Hansen TH, Fox J, Gunthard HF, Khanna N, Powrie F, Steel A, Gazzard B, Phillips RE, Frater J, Uhlig H, Klenerman P. Early and nonreversible decrease of CD161⁺⁺ /MAIT cells in HIV infection. *Blood.* 2013; 121(6): 951-61.
19. Cusini A, Vernazza PL, Yerly S, Decosterd LA, Ledergerber B, Fux CA, Rohrbach J, Widmer N, Hirschel B, Gaudenz R, Cavassini M, Klimkait T,

- Zenger F, Gutmann C, Opravil M, Gunthard HF, Swiss HIVCS. Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid. *J Acquir Immune Defic Syndr*. 2013; 62(1): 28-35.
20. Di Giallonardo F, Zagordi O, Duport Y, Leemann C, Joos B, Kunzli-Gontarczyk M, Bruggmann R, Beerenwinkel N, Gunthard HF, Metzner KJ. Next-Generation Sequencing of HIV-1 RNA Genomes: Determination of Error Rates and Minimizing Artificial Recombination. *PLoS One*. 2013; 8(9): e74249.
 21. Du Pasquier RA, Jilek S, Kalubi M, Yerly S, Fux CA, Gutmann C, Cusini A, Gunthard HF, Cavassini M, Vernazza PL, Swiss HIVCS. Marked increase of the astrocytic marker S100B in the cerebrospinal fluid of HIV-infected patients on LPV/r-monotherapy. *AIDS*. 2013; 27(2): 203-10.
 22. Ender M, Andreoni F, Zinkernagel AS, Schuepbach RA. Streptococcal SpeB Cleaved PAR-1 Suppresses ERK Phosphorylation and Blunts Thrombin-Induced Platelet Aggregation. *PLoS One*. 2013; 8(11): e81298.
 23. Fayet-Mello A, Buclin T, Guignard N, Cruchon S, Cavassini M, Grawe C, Gremlich E, Popp KA, Schmid F, Eap CB, Telenti A, Biollaz J, Decosterd LA, Martinez de Tejada B. Free and total plasma levels of lopinavir during pregnancy, at delivery and postpartum: implications for dosage adjustments in pregnant women. *Antivir Ther*. 2013; 18(2): 171-82.
 24. Fenner L, Egger M, Bodmer T, Furrer H, Ballif M, Battegay M, Helbling P, Fehr J, Gsponer T, Rieder HL, Zwahlen M, Hoffmann M, Bernasconi E, Cavassini M, Calmy A, Dolina M, Frei R, Janssens JP, Borrell S, Stucki D, Schrenzel J, Bottger EC, Gagneux S. HIV infection disrupts the sympatric host-pathogen relationship in human tuberculosis. *PLoS Genet*. 2013; 9(3): e1003318.
 25. Gallant JE, Koenig E, Andrade-Villanueva J, Chetchotisakd P, DeJesus E, Antunes F, Arasteh K, Moyle G, Rizzardini G, Fehr J, Liu Y, Zhong L, Callebaut C, Szwarcberg J, Rhee MS, Cheng AK. Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV type 1-infected patients: week 48 results. *J Infect Dis*. 2013; 208(1): 32-9.
 26. Gasser O, Brander C, Wolbers M, Brown NV, Rauch A, Gunthard HF, Battegay M, Hess C, Swiss HIVCS. Expansion of interferon-gamma-secreting HIV-specific T cells during successful antiretroviral therapy. *HIV Med*. 2013; 14(4):241-6.
 27. Grint, D; Peters, L; Reekie, J; Soriano, V; Kirk, O; Knysz, B; Suetnov, O; Lazzarin, A; Ledergerber, B; Rockstroh, J K; Mocroft, A. Stability of hepatitis C virus (HCV) RNA levels among interferon-naïve HIV/HCV-coinfected individuals treated with combination antiretroviral therapy. *HIV Med* 2013;14(6):370-378.
 28. Guennewig B, Roos M, Dogar AM, Gebert LF, Zagalak JA, Vongrad V, Metzner KJ, Hall J. Synthetic pre-microRNAs reveal dual-strand activity of miR-34a on TNF-alpha. *RNA*. 2013. [Epub ahead of print]
 29. Hassig A, Roos M, Etter A, Bossart W, Muller N, Schiesser M, Wuthrich RP, Fehr T. Association of BK viremia with human leukocyte antigen mismatches

and acute rejection, but not with type of calcineurin inhibitor. *Transpl Infect Dis*. 2013. [Epub ahead of print]

30. Hombach M, Wolfensberger A, Kuster SP, Bottger EC. Influence of clinical breakpoint changes from CLSI 2009 to EUCAST 2011 antimicrobial susceptibility testing guidelines on multidrug resistance rates of Gram-negative rods. *J Clin Microbiol*. 2013; 51(7): 2385-7.
31. Koller MT, van Delden C, Muller NJ, Baumann P, Lovis C, Marti HP, Fehr T, Binet I, De Geest S, Bucher HC, Meylan P, Pascual M, Steiger J. Design and methodology of the Swiss Transplant Cohort Study (STCS): a comprehensive prospective nationwide long-term follow-up cohort. *Eur J Epidemiol*. 2013;28(4): 347-55.
32. Kouyos R, Klein E, Grenfell B. Hospital-community interactions foster coexistence between methicillin-resistant strains of *Staphylococcus aureus*. *PLoS Pathog*. 2013; 9(2): e1003134.
33. Kovari H, de Melo Oliveira MD, Hauser P, Lauchli S, Meyer J, Weber R, Zbinden R. Decreased susceptibility of *Neisseria gonorrhoeae* isolates from Switzerland to Cefixime and Ceftriaxone: antimicrobial susceptibility data from 1990 and 2000 to 2012. *BMC Infect Dis*. 2013; 13: 603.
34. Kovari H, Sabin CA, Ledergerber B, Ryom L, Worm SW, Smith C, Phillips A, Reiss P, Fontas E, Petoumenos K, De Wit S, Morlat P, Lundgren JD, Weber R. Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: the data collection on adverse events of anti-HIV drugs study. *Clin Infect Dis*. 2013; 56(6): 870-9.
35. Kuster SP, Coleman BL, Raboud J, McNeil S, De Serres G, Gubbay J, Hatchette T, Katz KC, Loeb M, Low D, Mazzulli T, Simor A, McGeer AJ. Risk factors for influenza among health care workers during 2009 pandemic, Toronto, Ontario, Canada. *Emerg Infect Dis*. 2013; 19(4): 606-15.
36. Ledergerber B, Costagliola D, Lodwick R, Torti C, van Sighem A, Podzamczak D, Mocroft A, Dorrucchi M, Masquelier B, Günthard HF, de Luca A, Michalik C. Predictors of CD4+ T-Cell Counts of HIV Type 1-Infected Persons After Virologic Failure of All 3 Original Antiretroviral Drug Classes. *J Infect Dis*. 2013; 207(5):759-767.
37. Lesurtel M, Raptis DA, Melloul E, Schlegel A, Oberkofler C, El-Badry AM, Weber A, Mueller N, Dutkowski P, Clavien PA. Low platelet counts after liver transplantation predict early posttransplant survival: The 60-5 criterion. *Liver transplantation* 2013. [Epub ahead of print]
38. Leventhal GE, Günthard HF, Bonhoeffer S, Stadler T. Using an Epidemiological Model for Phylogenetic Inference Reveals Density Dependence in HIV Transmission. *Mol Biol Evol*. 2013. [Epub ahead of print]
39. Li JZ, Paredes R, Ribaud HJ, Kozal MJ, Svarovskaia ES, Johnson JA, Geretti AM, Metzner KJ, Jakobsen MR, Hullsiek KH, Ostergaard L, Miller MD, Kuritzkes DR. Impact of minority nonnucleoside reverse transcriptase inhibitor resistance

mutations on resistance genotype after virologic failure. *J Infect Dis.* 2013;207(6): 893-7.

40. Lubomirov R, Arab-Alameddine M, Rotger M, Fayet-Mello A, Martinez R, Guidi M, di Iulio J, Cavassini M, Gunthard HF, Furrer H, Marzolini C, Bernasconi E, Calmy A, Buclin T, Decosterd LA, Csajka C, Telenti A, Swiss HIVCS. Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals. *Pharmacogenet Genomics.* 2013; 23(1): 9-18.
41. Manuel O, Kralidis G, Mueller NJ, Hirsch HH, Garzoni C, van Delden C, Berger C, Boggian K, Cusini A, Koller MT, Weisser M, Pascual M, Meylan PR. Impact of antiviral preventive strategies on the incidence and outcomes of cytomegalovirus disease in solid organ transplant recipients. *Am J Transplant.* 2013; 13(9): 2402-10.
42. Maurer FP, Keller PM, Beuret C, Joha C, Achermann Y, Gubler J, Bircher D, Karrer U, Fehr J, Zimmerli L, Bloemberg GV. Close geographic association of human neoehrlichiosis and tick populations carrying "Candidatus Neoehrlichia mikurensis" in eastern Switzerland. *J Clin Microbiol.* 2013; 51(1): 169-76.
43. Mertz D, Kim TH, Johnstone J, Lam PP, Science M, Kuster SP, Fadel SA, Tran D, Fernandez E, Bhatnagar N, Loeb M. Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis. *BMJ.* 2013;347: f5061.
44. Metzner KJ, Scherrer AU, Preiswerk B, Joos B, von Wyl V, Leemann C, Rieder P, Braun D, Grube C, Kuster H, Boni J, Yerly S, Klimkait T, Aubert V, Furrer H, Battegay M, Vernazza PL, Cavassini M, Calmy A, Bernasconi E, Weber R, Gunthard HF, Swiss HIVCS. Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection. *J Infect Dis.* 2013; 208(7): 1102-12.
45. Millard AL, Valli PV, Stussi G, Mueller NJ, Yung GP, Seebach JD. Brief Exercise Increases Peripheral Blood NK Cell Counts without Immediate Functional Changes, but Impairs their Responses to ex vivo Stimulation. *Front Immunol.* 2013; 4: 125.
46. Mocroft A, Furrer HJ, Miro JM, Reiss P, Mussini C, Kirk O, Abgrall S, Ayayi S, Bartmeyer B, Braun D, Castagna A, d'Arminio Monforte A, Gazzard B, Gutierrez F, Hurtado I, Jansen K, Meyer L, Munoz P, Obel N, Soler-Palacin P, Papadopoulos A, Raffi F, Ramos JT, Rockstroh JK, Salmon D, Torti C, Warszawski J, de Wit S, Zangerle R, Fabre-Colin C, Kjaer J, Chene G, Grarup J, Lundgren JD. The incidence of AIDS-defining illnesses at a current CD4 count \geq 200 cells/ μ L in the post-combination antiretroviral therapy era. *Clin Infect Dis.* 2013; 57(7): 1038-47.
47. Mocroft A, Phillips AN, Gatell J, Horban A, Ledergerber B, Zilmer K, Jevtovic D, Maltez F, Podlekareva D, Lundgren JD, Euro SsiE. CD4 cell count and viral load-specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use. *AIDS.* 2013; 27(6): 907-18.

48. Mohammadi P, Desfarges S, Bartha I, Joos B, Zangger N, Munoz M, Gunthard HF, Beerenwinkel N, Telenti A, Ciuffi A. 24 hours in the life of HIV-1 in a T cell line. *PLoS Pathog.* 2013; 9(1): e1003161.
49. Monforte A, Reiss P, Ryom L, El-Sadr W, Dabis F, De Wit S, Worm SW, Law MG, Weber R, Kirk O, Pradier C, Phillips AN, Lundgren JD, Sabin CA. Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease events. *AIDS.* 2013; 27(3): 407-15.
50. Oesch Nemeth G, Nemeth J, Altpeter E, Ritz N. Epidemiology of childhood tuberculosis in Switzerland between 1996 and 2011. *European journal of pediatrics.* 2013. [Epub ahead of print]
51. Orasch C, Marchetti O, Garbino J, Schrenzel J, Zimmerli S, Muhlethaler K, Rossi M, Pfyffer G, Ruef C, Fehr J, Zbinden R, Calandra T, Bille J. Candida Species Distribution and Antifungal Susceptibility Testing According to EUCAST and New vs. Old CLSI Clinical Breakpoints: a Six-Year Prospective Candidemia Survey from the Fungal Infection Network of Switzerland (FUNGINOS). *Clin Microbiol Infect.* 2013. [Epub ahead of print].
52. Preiswerk B, Rudiger A, Fehr J, Corti N. Experience with daptomycin daily dosing in ICU patients undergoing continuous renal replacement therapy. *Infection.* 2013; 41(2): 553-7.
53. Quiblier C, Seidl K, Roschitzki B, Zinkernagel AS, Berger-Bachi B, Senn MM. Secretome analysis defines the major role of SecDF in *Staphylococcus aureus* virulence. *PLoS One.* 2013; 8(5): e63513.
54. Rohrbach J, Stickel F, Schmid P, Thormann W, Kovari H, Scherrer A, Gunthard HF, Vuichard D, Cavassini M, Ambrosioni J, Bernasconi E, Furrer H, Rauch A. Changes in biomarkers of liver disease during successful combination antiretroviral therapy in HIV/HCV-coinfected individuals. *Antivir Ther.* 2013. [Epub ahead of print]
55. Rotger M, Glass TR, Junier T, Lundgren J, Neaton JD, Poloni ES, van 't Wout AB, Lubomirov R, Colombo S, Martinez R, Rauch A, Gunthard HF, Neuhaus J, Wentworth D, van Manen D, Gras LA, Schuitemaker H, Albini L, Torti C, Jacobson LP, Li X, Kingsley LA, Carli F, Guaraldi G, Ford ES, Sereti I, Hadigan C, Martinez E, Arnedo M, Egana-Gorrone L, Gatell JM, Law M, Bendall C, Petoumenos K, Rockstroh J, Wasmuth JC, Kabamba K, Delforge M, De Wit, Berger F, Mauss S, de Paz Sierra M, Losso M, Belloso WH, Leyes M, Campins A, Mondini A, De Luca A, Bernardino I, Barriuso-Iglesias M, Torrecilla-Rodriguez A, Gonzalez-Garcia J, Arribas JR, Fanti I, Gel S, Puig J, Negredo E, Gutierrez M, Domingo P, Fischer J, Fatkenheuer G, Alonso-Villaverde C, Macken A, Woo J, McGinty T, Mallon P, Mangili A, Skinner S, Wanke CA, Reiss P, Weber R, Bucher HC, Fellay J, Telenti A, Tarr PE. Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons. *Clin Infect Dis.* 2013; 57(1): 112-21.
56. Sabin CA, Ryom L, Kovari H, Kirk O, de Wit S, Law M, Reiss P, Dabis F, Pradier C, El-Sadr W, Monforte A, Kamara D, Phillips AN, Lundgren JD. Association between ALT level and the rate of cardio/cerebrovascular events in

- HIV-positive individuals: the D: A: D study. *J Acquir Immune Defic Syndr*. 2013;63(4): 456-63.
57. Sabin CA, Ryom L, De Wit S, Mocroft A, Phillips AN, Worm SW, Weber R, D'Arminio Monforte A, Reiss P, Kamara D, El-Sadr W, Pradier C, Dabis F, Law M, Lundgren J. Associations between immune depression and cardiovascular events in HIV infection. *AIDS* 2013; 27(17):2735-2748.
 58. Sax H, Clack L, Touveneau S, da Liberdade Jantarada F, Pittet D, Zingg W, on behalf of the PROHIBIT study group. Implementation of infection control best practice in intensive care units throughout Europe: a mixed-method evaluation study. *Implement Sci*. 2013;19;8:24.
 59. Schupbach J, Gebhardt MD, Scherrer AU, Bisset LR, Niederhauser C, Regenass S, Yerly S, Aubert V, Suter F, Pfister S, Martinetti G, Andreutti C, Klimkait T, Brandenberger M, Gunthard HF, Swiss HIVCS. Simple estimation of incident HIV infection rates in notification cohorts based on window periods of algorithms for evaluation of line-immunoassay result patterns. *PLoS One*. 2013;8(8): e71662.
 60. Seidl K, Zinkernagel AS. The MTT assay is a rapid and reliable quantitative method to assess *Staphylococcus aureus* induced endothelial cell damage. *J Microbiol Methods*. 2013; 92(3): 307-9.
 61. Shireff G, Alizon S, Cori A, Guenthard HF, Laeyendecker O, Van Sighem A, Bezemer D, Fraser C. How effectively can HIV phylogenies be used to measure heritability? *Evolution, Medicine, and Public Health*. 2013: 209-24.
 62. Smith MZ, Bastidas S, Karrer U, Oxenius A. Impact of antigen specificity on CD4+ T cell activation in chronic HIV-1 infection. *BMC Infect Dis*. 2013; 13: 100.
 63. Taylor N, Grabmeier-Pfistershammer K, Egle A, Greil R, Rieger A, Ledergerber B, Oberkofler H. Cobas Ampliprep/Cobas TaqMan HIV-1 v2.0 Assay: Consequences at the Cohort Level. *PLoS ONE* 2013; 8(8):e74024.
 64. Tchang VS, Mekker A, Siegmund K, Karrer U, Pieters J. Diverging role for coronin 1 in antiviral CD4(+) and CD8(+) T cell responses. *Mol Immunol*. 2013;56(4): 683-92.
 65. Uchiyama S, Andreoni F, Zurcher C, Schilcher K, Ender M, Madon J, Matt U, Ghosh P, Nizet V, Schuepbach RA, Zinkernagel AS. Coiled-coil irregularities of the M1 protein structure promote M1-fibrinogen interaction and influence group A *Streptococcus* host cell interactions and virulence. *J Mol Med (Berl)*. 2013;91(7): 861-9.
 66. Uçkay I, Sax H, Gayet-Ageron A, Ruef C, Mühlemann K, Troillet N, Petignat C, Bernasconi E, Balmelli C, Widmer A, Boubaker K, Pittet D. High proportion of healthcare-associated urinary tract infection in the absence of prior exposure to urinary catheter: a cross-sectional study. *Antimicrob Resist Infect Control*. 2013;2(1):5.
 67. Ueda S, Uchiyama S, Azzi T, Gysin C, Berger C, Bernasconi M, Harabuchi Y, Zinkernagel AS, Nadal D. Oropharyngeal Group A *Streptococcal* Colonization

- Disrupts Latent Epstein-Barr Virus Infection. *J Infect Dis.* 2013. [Epub ahead of print]
68. Veloso TR, Zbinden A, Andreoni F, Giddey M, Vouillamoz J, Moreillon P, Zinkernagel AS, Entenza JM. *Streptococcus tigurinus* is highly virulent in a rat model of experimental endocarditis. *International Journal of Medical Microbiology* 2013; 303(8):498-504.
 69. von Wyl V, Klimkait T, Yerly S, Nicca D, Furrer H, Cavassini M, Calmy A, Bernasconi E, Boni J, Aubert V, Gunthard HF, Bucher HC, Glass TR, Swiss HIVCS. Adherence as a predictor of the development of class-specific resistance mutations: the Swiss HIV Cohort Study. *PLoS One.* 2013; 8(10):e77691.
 70. Vratskikh O, Stiasny K, Zlatkovic J, Tsouchnikas G, Jarmer J, Karrer U, Roggendorf M, Roggendorf H, Allwinn R, Heinz FX. Dissection of antibody specificities induced by yellow fever vaccination. *PLoS Pathog.* 2013; 9(6):e1003458.
 71. Wandeler G, Gsponer T, Bihl F, Bernasconi E, Cavassini M, Kovari H, Schmid P, Battegay M, Calmy A, Egger M, Furrer H, Rauch A. Hepatitis B virus infection is associated with impaired immunological recovery during niretroviral therapy in the Swiss HIV Cohort Study. *J Infect Dis.* 2013; 208(9): 1454-8.
 72. Wang Q, Young J, Bernasconi E, Cavassini M, Vernazza P, Hirschel B, Weber R, Furrer H, Stoeckle M, Bucher HC, Fux C. The prevalence of erectile dysfunction and its association with antiretroviral therapy in HIV-infected men: the Swiss HIV Cohort Study. *Antivir Ther.* 2013; 18(3): 337-44.
 73. Weber R, Ruppik M, Rickenbach M, Spoerri A, Furrer H, Battegay M, Cavassini M, Calmy A, Bernasconi E, Schmid P, Flepp M, Kowalska J, Ledergerber B. Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. *HIV Med.* 2013; 14(4): 195-207.
 74. Weibel P, Ender M, Madon J, Zinkernagel A, Schuepbach RA. Selection vector for direct cloning of proof reading polymerase chain reaction products based on the lethal *ccdB* gene in *Escherichia Coli*. *Advances in Microbiology.* 2013; 03(1):14-20.
 75. Wolfensberger A, Sax H, Weber R, Zbinden R, Kuster SP, Hombach M. Change of Antibiotic Susceptibility Testing Guidelines from CLSI to EUCAST: Influence on Cumulative Hospital Antibiograms. *PLoS One.* 2013; 8(11):e79130.

Case Reports

1. Braun DL, Hasse BK, Stricker J, Fehr JS. Prosthetic valve endocarditis caused by *Propionibacterium* species successfully treated with coadministered rifampin: report of two cases. *BMJ Case Rep.* 2013 [Epub ahead of print]
2. Nobile A, Schuepbach RA, Flepp M, Maggiorini M, Gunthard H, Zinkernagel AS. [Hoarseness after a trip to the United States of America]. *Praxis (Bern 1994).* 2013; 102(22): 1377-81.

3. Sommerstein, R; Ramsay, D; Dubuis, O; Waser, S; Aebbersold, F; Vogt, M. Fatal *Neisseria sicca* endocarditis. *Infection* 2013; 41(3):747-749.
4. Wolfensberger A, Benz R, Russi EW, Tinguely M, Keller C, Gerber B. [Dyspnoea, cough and B symptoms in a 40-year-old woman]. *Internist (Berl)*. 2013; 54(8): 1011-5.

Übersichtsartikel / Reviews

1. Allegranzi B, Sax H, Pittet D. Hand hygiene and healthcare system change within multi-modal promotion: a narrative review. *J Hosp Infect*. 2013 Feb;83 Suppl 1:S3-10.
2. Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, Shafer RW, Wensing AM, Richman DD. Update of the drug resistance mutations in HIV-1: March 2013. *Topics in antiviral medicine*. 2013; 21(1): 6-14.
3. Hasse B, Husmann L, Zinkernagel A, Weber R, Lachat M, Mayer D. Vascular graft infections. *Swiss Med Wkly*. 2013; 143: w13754.
4. Tarr P, Baumann K, Wallnöfer A, Zimmerli F, Maritz D, Burri U, Egger M, Clerc O, Bernasconi E, Kovari H, Senn L. Akute Harnwegsinfektionen, Teil 1: HWI in der Praxis. *Schweiz Med Forum*. 2013; 13(24): 467-71.
5. Tarr, P; Baumann, K; Wallnöfer, A; Zimmerli, F; Maritz, D; Burri, U; Egger, M; Clerc, O; Bernasconi, E; Kovari, H; Senn, L. Akute Harnwegsinfektionen Teil 2 : HWI im Spital und Alters- und Pflegeheim. *Swiss Medical Forum, Schweizerisches Medizin-Forum*. 2013;13(24):472-475.
6. von Braun A, Gunthard H. [HIV infection and antiretroviral therapy: basic principles of treatment and impacts on other therapies]. *Praxis (Bern 1994)*. 2013; 102(1): 5-13; quiz 4-5.

Buchkapitel

1. Weber, R; Fontana, A (2013). Status febrilis. In: Battegay, E. Siegenthalers Differenzialdiagnose : innere Krankheiten - vom Symptom zur Diagnose. Stuttgart, 111-216.

Andere Arbeiten

1. Bosshard PP, Graf N, Knaute DF, Kundig T, Lautenschlager S, Weber R. Response of *Treponema pallidum* particle agglutination test titers to treatment of syphilis. *Clin Infect Dis*. 2013; 56(3): 463-4.
2. Conen A, Wang Q, Fehr J. Authors reply to the letter to the editor by Carrieri et al. HIV and alcohol - the ongoing debate. *J Acquir Immune Defic Syndr*. 2013 Dec 16. [Epub ahead of print]
3. Cusini A, Ledergerber B, Widmer N, Gunthard HF. Response to Calcagno comment on "Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid". *J Acquir Immune Defic Syndr*. 2013; 64(2): e14-5.

4. Fehr J, Nicca D, Langewitz W, Haerry D, Battegay M. Assessing HIV-positive Persons' Readiness to Start and Maintain ART. In the treatment guidelines of the European AIDS Clinical Society, Version 7, 2013. www.eacs.eu/guidelines.
5. Maurer FP, Maggio EM, Roth TN, Kuster SP, Bloemberg G. A Well-Preserved Culprit. Clin Infect Dis. 2013; 45(5): 747-8.

Habilitationen

1. Kuster SP. Epidemiology of influenza and Influenza-related Infections in the Community and the Healthcare Setting. Erteilung der Venia legendi für das Gebiet Infektiologie. Habilitation an der Universität Zürich, 2013.

Dissertationen

1. Tchang, V. The role of coronin 1 during cell mediated immune responses. Dissertation an der Universität Zürich (MNF), 2013. Leitung: PD Dr. Urs Karrer

Masterarbeiten

1. Drescher S. Treatment-naive individuals make up a majority of sources of transmitted HIV-1 drug-resistance found in MSMs in the Swiss HIV Cohort Study. Masterarbeit an der Universität Zürich (MNF), 2013. Leitung: Dr. Roger Kouyos
2. Furrer A. Induction of small colony variants of Staphylococcus aureus by low pH. Masterarbeit an der Universität Zürich (Medizinische Fakultät), 2013. Leitung: PD Dr. Annelies Zinkernagel
3. Lüthi Z. A Cluster of Invasive Aspergillosis After Solid Organ Transplantation: Identification of Modifiable Risk Factors. Masterarbeit an der Universität Zürich (Medizinische Fakultät), 2013. Leitung: Prof. Dr. Nicolas Müller
4. Sulser P. Platelet count is a potent predictor of outcome after liver transplantation. Masterarbeit an der Universität Zürich (Medizinische Fakultät), 2013. Leitung: Prof. Dr. Nicolas Müller
5. Tarnutzer A. Effect of clindamycin and pooled human immunoglobulin on streptococcal virulence factors in vitro. Masterarbeit an der Universität Zürich (MNF), 2013. Leitung: PD Dr. Annelies Zinkernagel